Mirum Pharmaceuticals, Inc.

    Jurisdiction
    United States
    ISIN
    US6047491013 (MIRM)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    6 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Read full profile

    Fundamentals

    Net revenue
    €366.05M
    Gross margin
    79.0%
    EBIT
    -€48.68M
    EBIT margin
    -13.3%
    Net income
    -€49.95M
    Net margin
    -13.6%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €517.01M +41.2% €1.94M -103.9%
    €611.23M +18.2% €60.56M +3,014.0%
    €725.03M +18.6% €129.83M +114.4%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    BJERKHOLT ERIC CHIEF FINANCIAL OFFICER -8K $0.00 -$0.00
    Peetz Christopher CHIEF EXECUTIVE OFFICER -40K $62.00 -$2.48M
    Howe Jolanda SVP, GLOBAL CONTROLLER -10K $58.00 -$580.00K
    Peetz Christopher CHIEF EXECUTIVE OFFICER -40K $55.25 -$2.21M

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 189K $8.49M +87K Buy

    Earnings Calls

    Latest earnings call: May 8, 2024 (Q1 2024)

    Add to watchlist

    Notifications